{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:50Z","timestamp":1761894770125},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Prostate Cancer"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.3816\/cgc.2002.n.016","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:06:51Z","timestamp":1221095211000},"page":"145-152","source":"Crossref","is-referenced-by-count":42,"title":["Zoledronic Acid Significantly Reduces Pathologic Fractures in Patients with Advanced-Stage Prostate Cancer Metastatic to Bone"],"prefix":"10.3816","volume":"1","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2002.n.016_bib1","author":"Ries"},{"key":"10.3816\/CGC.2002.n.016_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","article-title":"Global cancer statistics","volume":"49","author":"Parkin","year":"1999","journal-title":"CA Cancer J Clin"},{"issue":"suppl 12","key":"10.3816\/CGC.2002.n.016_bib3","doi-asserted-by":"crossref","first-page":"S2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"issue":"suppl 8","key":"10.3816\/CGC.2002.n.016_bib4","doi-asserted-by":"crossref","first-page":"S1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CGC.2002.n.016_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(05)67149-2","article-title":"Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline","volume":"164","author":"Berruti","year":"2000","journal-title":"J Urol"},{"issue":"suppl 6A","key":"10.3816\/CGC.2002.n.016_bib6","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0090-4295(99)00448-3","article-title":"Complications of advanced prostate cancer","volume":"54","author":"Smith","year":"1999","journal-title":"Urology"},{"key":"10.3816\/CGC.2002.n.016_bib7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.3816\/CGC.2002.n.016_bib8","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2002.n.016_bib9","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"issue":"suppl 1","key":"10.3816\/CGC.2002.n.016_bib10","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0090-4295(01)01251-1","article-title":"Osteoporosis due to androgen deprivation therapy in men with prostate cancer","volume":"58","author":"Daniell","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2002.n.016_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2002.n.016_bib12","first-page":"260","article-title":"Determinants of reduced survival following hip fractures in men","volume":"319","author":"Poor","year":"1995","journal-title":"Clin Orthop"},{"key":"10.3816\/CGC.2002.n.016_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF01626602","article-title":"Age-related hip fractures in men: clinical spectrum and short-term outcomes","volume":"5","author":"Poor","year":"1995","journal-title":"Osteoporos Int"},{"key":"10.3816\/CGC.2002.n.016_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2002.n.016_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0090-4295(02)01633-3","article-title":"Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era","volume":"60","author":"Oefelein","year":"2002","journal-title":"Urology"},{"issue":"suppl 11","key":"10.3816\/CGC.2002.n.016_bib16","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0093-7754(01)90229-5","article-title":"Bone metastases: approaches to management","volume":"28","author":"Janjan","year":"2001","journal-title":"Semin Oncol"},{"key":"10.3816\/CGC.2002.n.016_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2165\/00002512-200118120-00002","article-title":"Strategies for management of prostate cancer-related bone pain","volume":"18","author":"Pelger","year":"2001","journal-title":"Drugs Aging"},{"key":"10.3816\/CGC.2002.n.016_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00259-001-0728-7","article-title":"Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton","volume":"29","author":"Soerdjbalie-Maikoe","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"10.3816\/CGC.2002.n.016_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2002.n.016_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2002.n.016_bib21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CGC.2002.n.016_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2002.n.016_bib23","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2002.n.016_bib24","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.3816\/CGC.2002.n.016_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","article-title":"Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption","volume":"55","author":"Green","year":"2002","journal-title":"Drug Dev Res"},{"key":"10.3816\/CGC.2002.n.016_bib26","first-page":"6001","article-title":"Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts","volume":"60","author":"Reinholz","year":"2000","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2002.n.016_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, doubleblind, placebo-controlled study","volume":"141","author":"Smith","year":"1989","journal-title":"J Urol"},{"key":"10.3816\/CGC.2002.n.016_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer","volume":"24","author":"Elomaa","year":"1992","journal-title":"Int Urol Nephrol"},{"key":"10.3816\/CGC.2002.n.016_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain\u2014a double-blind placebo-controlled study in patients with prostate cancer","volume":"76","author":"Kylmala","year":"1997","journal-title":"Br J Cancer"},{"key":"10.3816\/CGC.2002.n.016_bib30","first-page":"177a","article-title":"Randomized placebo controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study","volume":"21","author":"Ernst","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CGC.2002.n.016_bib31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CGC.2002.n.016_bib32","first-page":"4717","article-title":"The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer","volume":"17","author":"Strang","year":"1997","journal-title":"Anticancer Res"},{"issue":"suppl 2","key":"10.3816\/CGC.2002.n.016_bib33","first-page":"S45","article-title":"The new bisphosphonate, ZOMETA\u00ae (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: a comparison to pamidronate","volume":"20","author":"Lipton","year":"2001","journal-title":"Cancer Invest"},{"key":"10.3816\/CGC.2002.n.016_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(87)90487-6","article-title":"Etidronate disodium in the management of malignancy-related hypercalcemia","volume":"82","author":"Hasling","year":"1987","journal-title":"Am J Med"},{"key":"10.3816\/CGC.2002.n.016_bib35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0090-4295(88)90410-4","article-title":"Treatment of painful prostatic bone metastases with oral etidronate disodium","volume":"32","author":"Carey","year":"1988","journal-title":"Urology"},{"key":"10.3816\/CGC.2002.n.016_bib36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","article-title":"The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer","volume":"165","author":"Heidenreich","year":"2001","journal-title":"J Urol"},{"key":"10.3816\/CGC.2002.n.016_bib37","first-page":"145","article-title":"Fitting new modalities into practice guidelines","volume":"11","author":"Theriault","year":"1997","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CGC.2002.n.016_bib38","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2002.n.016_bib39","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CGC.2002.n.016_bib40","unstructured":"Saad F, Gleason D, Small E, et al. Zoledronic acid is effective for the treatment of bone metastases in men with advanced prostate cancer. Poster presented at: 3rd International Consultation on Prostate Cancer; June 21-23, 2002; Paris, France."},{"key":"10.3816\/CGC.2002.n.016_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CGC.2002.n.016_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2002.n.016_bib43","unstructured":"Smith MR, Shasha D, Mansour R, Zinner N. ZOMETA\u00ae increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Presented at 3rd North American Symposium: Skeletal Complications of Malignancy; Bethesda, Maryland."},{"key":"10.3816\/CGC.2002.n.016_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00015458.1998.12098427","article-title":"Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures","volume":"98","author":"Fourneau","year":"1998","journal-title":"Acta Chir Belg"},{"key":"10.3816\/CGC.2002.n.016_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00402-001-0359-2","article-title":"Surgery of skeletal metastases","volume":"122","author":"Katzer","year":"2002","journal-title":"Arch Orthop Trauma Surg"},{"issue":"suppl 12","key":"10.3816\/CGC.2002.n.016_bib46","doi-asserted-by":"crossref","first-page":"S2940","DOI":"10.1002\/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W","article-title":"Complications of bone metastases: surgical management","volume":"88","author":"Healey","year":"2000","journal-title":"Cancer"}],"container-title":["Clinical Prostate Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154003521170138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154003521170138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:35:17Z","timestamp":1631777717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154003521170138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S154003521170138X"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2002.n.016","relation":{},"ISSN":["1540-0352"],"issn-type":[{"value":"1540-0352","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}